USA |NASDAQ |USD
Revenues were $0.00.
The company reported a net income of $-152.14M.
Cerevel Therapeutics Holdings, Inc reported a free cash flow of $-136.69M for its fiscal year, compared to $-71.82M a year ago.
The company ended the fiscal year with $33.01M in total debt, an increase of 16.17% compared to the previous year.